Fisher Asset Management
CTXR icon

Fisher Asset Management’s Citius Pharmaceuticals CTXR Stock Holding History

Fisher Asset Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,800
Closed -$51.2K – 1017
2024
Q4 		$51.2K Buy
+12,800
New +$86.2K ﹤0.01% 965

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCA
Bay Colony Advisors Concord, Massachusetts $903M AUM 33.67% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fisher Asset Management's CTXR Position: Q1 2025 in Review

Fisher Asset Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2025, closing a stake of 12,800 shares — an estimated $51.2K sold.

Fisher Asset Management first reported a position in CTXR in Q4 2024 and held it in 1 quarter. The position peaked at $51.2K in Q4 2024. 28 funds tracked by Wall St. Rank hold CTXR as of Q1 2025.

  • Fisher Asset Management reported no remaining Citius Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Fisher Asset Management sold 12,800 Citius Pharmaceuticals shares in Q1 2025, an estimated $51.2K.
  • Fisher Asset Management first reported a position in Citius Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Fisher Asset Management's Citius Pharmaceuticals position peaked at $51.2K in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2025.

Based on Fisher Asset Management's 13F filing for Q1 2025, filed 14 May 2025.